The global Gout Medications market was valued at US$ 3874 million in 2025 and is anticipated to reach US$ 6391 million by 2032, at a CAGR of 7.5% from 2026 to 2032.

Gout Medications Market

Gout medications comprise agents for prevention and treatment of gout and hyperuricemia, including anti-inflammatory analgesics for acute attacks, xanthine oxidase inhibitors and uricosurics for long-term uric acid control, and emerging targeted small molecules and biologics. The therapeutic aim extends beyond acute pain relief to sustained control of serum urate to prevent joint destruction, tophi formation, and renal complications. With expanding populations affected by metabolic disorders and the widespread adoption of chronic disease management, clinical practice is shifting from episodic attack treatment toward continuous metabolic control, increasing demand for combination therapies, personalized regimens, and adherence-supporting solutions. Pharmaceutical innovations in novel molecular targets, extended-release formulations, and integration with digital therapeutics are set to enhance both market value and patient outcomes, creating new requirements across upstream raw materials, manufacturing, and distribution networks.The average gross profit margin in this industry is 60%。

Structural growth opportunities continue to expand the gout medications market globally. Corporate annual reports and brokerage analyses consistently highlight that the growing chronic metabolic population, increased patient awareness of long-term management, and broader reimbursement coverage together amplify sustained demand for uric acid control and complication prevention therapies. R&D investment is shifting toward precision targets and long-acting delivery, enabling differentiated medicines with adherence advantages to rapidly capture market positions. The commercialization of digital health and chronic care services also offers pharmaceutical firms embedded therapy models and monetizable value-added services, attracting capital and marketing focus.

Despite clear opportunities, the sector faces pressures from post-patent generic incursions, intensifying price competition, and tightened regulatory and compliance requirements. Corporate reports flag risks related to concentrated raw material supply chains and rising environmental compliance costs; broker research warns that safety controversies or regulatory constraints can rapidly alter a drug’s market outlook. Moreover, the chronic nature of gout treatment and suboptimal patient adherence mean many potential market opportunities face conversion barriers into sustained prescriptions and long-term medication use, requiring firms to invest more in product design, patient support, and channel capabilities to secure commercial returns.

Clinical and end-market demand is shifting from acute attack treatment toward prevention and long-term management, with hospitals, specialty clinics, and retail channels forming a multi-channel distribution ecosystem. Annual reports and government health policies show that the expansion of community chronic care and online medical services is reshaping prescribing pathways and patient purchasing behavior, prompting pharmaceutical companies to pivot from single-course promotion to long-term adherence support and integrated treatment solutions. Rising demand for customized combination therapies, extended-release formulations, and follow-up services gives an edge to firms with full-stack channel and service capabilities.

The upstream segment for gout medications centers on high-purity organic intermediates, key small-molecule APIs, and formulation excipients, with supply chains reliant on large-scale synthesis suppliers. Annual reports indicate that upstream capacity deployment and GMP compliance are critical to ensuring product quality and delivery; broker and regulatory communications emphasize the importance of environmental compliance and supply diversification. As novel molecules and complex formulations increase, upstream firms must continue investing in green chemistry, process scale-up, and stringent quality controls to meet downstream commercial expectations for reliable, traceable, and compliant supply.

This report delivers a comprehensive overview of the global Gout Medications market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gout Medications. The Gout Medications market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Gout Medications market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Gout Medications manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Gout Medications Market Report

Report Metric	Details
Report Name	Gout Medications Market
Accounted market size in 2025	US$ 3874 million
Forecasted market size in 2032	US$ 6391 million
CAGR	7.5%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Febuxostat Benzbromarone NSAIDs Colchicine Glucocorticoids Allopurinol Other
Segment by Application	Primary Gout Secondary Gout
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Takeda Pharmaceuticals, Hermann Germany, Aspen, Teijin Pharma, Horizon Pharmaceuticals, Novartis, Wanbang Biopharmaceuticals, Hengrui Medicine, London Reddy, East Sunshine Pharmaceuticals, Kunming Pharmaceuticals, Heilongjiang Auridanide, Jingde Pharmaceutical Factory, Tianjie Biopharmaceuticals, Shanghai Pharmaceuticals, Chengdu Taihe Health
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Gout Medications companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Gout Medications Market growing?

Ans: The Gout Medications Market witnessing a CAGR of 7.5% during the forecast period 2026-2032.

What is the Gout Medications Market size in 2032?

Ans: The Gout Medications Market size in 2032 will be US$ 6391 million.

Who are the main players in the Gout Medications Market report?

Ans: The main players in the Gout Medications Market are Takeda Pharmaceuticals, Hermann Germany, Aspen, Teijin Pharma, Horizon Pharmaceuticals, Novartis, Wanbang Biopharmaceuticals, Hengrui Medicine, London Reddy, East Sunshine Pharmaceuticals, Kunming Pharmaceuticals, Heilongjiang Auridanide, Jingde Pharmaceutical Factory, Tianjie Biopharmaceuticals, Shanghai Pharmaceuticals, Chengdu Taihe Health

What are the Application segmentation covered in the Gout Medications Market report?

Ans: The Applications covered in the Gout Medications Market report are Primary Gout, Secondary Gout

What are the Type segmentation covered in the Gout Medications Market report?

Ans: The Types covered in the Gout Medications Market report are Febuxostat, Benzbromarone, NSAIDs, Colchicine, Glucocorticoids, Allopurinol, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Gout Medications Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Febuxostat

1.2.3 Benzbromarone

1.2.4 NSAIDs

1.2.5 Colchicine

1.2.6 Glucocorticoids

1.2.7 Allopurinol

1.2.8 Other

1.3 Market by Application

1.3.1 Global Gout Medications Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Primary Gout

1.3.3 Secondary Gout

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Gout Medications Market Perspective (2021–2032)

2.2 Global Gout Medications Growth Trends by Region

2.2.1 Global Gout Medications Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Gout Medications Historic Market Size by Region (2021–2026)

2.2.3 Gout Medications Forecasted Market Size by Region (2027–2032)

2.3 Gout Medications Market Dynamics

2.3.1 Gout Medications Industry Trends

2.3.2 Gout Medications Market Drivers

2.3.3 Gout Medications Market Challenges

2.3.4 Gout Medications Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Gout Medications Players by Revenue

3.1.1 Global Top Gout Medications Players by Revenue (2021–2026)

3.1.2 Global Gout Medications Revenue Market Share by Players (2021–2026)

3.2 Global Top Gout Medications Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Gout Medications Revenue

3.4 Global Gout Medications Market Concentration Ratio

3.4.1 Global Gout Medications Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Gout Medications Revenue in 2025

3.5 Global Key Players of Gout Medications Head Offices and Areas Served

3.6 Global Key Players of Gout Medications, Products and Applications

3.7 Global Key Players of Gout Medications, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Gout Medications Breakdown Data by Type

4.1 Global Gout Medications Historic Market Size by Type (2021–2026)

4.2 Global Gout Medications Forecasted Market Size by Type (2027–2032)

5 Gout Medications Breakdown Data by Application

5.1 Global Gout Medications Historic Market Size by Application (2021–2026)

5.2 Global Gout Medications Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Gout Medications Market Size (2021–2032)

6.2 North America Gout Medications Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Gout Medications Market Size by Country (2021–2026)

6.4 North America Gout Medications Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Gout Medications Market Size (2021–2032)

7.2 Europe Gout Medications Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Gout Medications Market Size by Country (2021–2026)

7.4 Europe Gout Medications Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Gout Medications Market Size (2021–2032)

8.2 Asia-Pacific Gout Medications Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Gout Medications Market Size by Region (2021–2026)

8.4 Asia-Pacific Gout Medications Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Gout Medications Market Size (2021–2032)

9.2 Latin America Gout Medications Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Gout Medications Market Size by Country (2021–2026)

9.4 Latin America Gout Medications Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Gout Medications Market Size (2021–2032)

10.2 Middle East & Africa Gout Medications Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Gout Medications Market Size by Country (2021–2026)

10.4 Middle East & Africa Gout Medications Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Takeda Pharmaceuticals

11.1.1 Takeda Pharmaceuticals Company Details

11.1.2 Takeda Pharmaceuticals Business Overview

11.1.3 Takeda Pharmaceuticals Gout Medications Introduction

11.1.4 Takeda Pharmaceuticals Revenue in Gout Medications Business (2021–2026)

11.1.5 Takeda Pharmaceuticals Recent Development

11.2 Hermann Germany

11.2.1 Hermann Germany Company Details

11.2.2 Hermann Germany Business Overview

11.2.3 Hermann Germany Gout Medications Introduction

11.2.4 Hermann Germany Revenue in Gout Medications Business (2021–2026)

11.2.5 Hermann Germany Recent Development

11.3 Aspen

11.3.1 Aspen Company Details

11.3.2 Aspen Business Overview

11.3.3 Aspen Gout Medications Introduction

11.3.4 Aspen Revenue in Gout Medications Business (2021–2026)

11.3.5 Aspen Recent Development

11.4 Teijin Pharma

11.4.1 Teijin Pharma Company Details

11.4.2 Teijin Pharma Business Overview

11.4.3 Teijin Pharma Gout Medications Introduction

11.4.4 Teijin Pharma Revenue in Gout Medications Business (2021–2026)

11.4.5 Teijin Pharma Recent Development

11.5 Horizon Pharmaceuticals

11.5.1 Horizon Pharmaceuticals Company Details

11.5.2 Horizon Pharmaceuticals Business Overview

11.5.3 Horizon Pharmaceuticals Gout Medications Introduction

11.5.4 Horizon Pharmaceuticals Revenue in Gout Medications Business (2021–2026)

11.5.5 Horizon Pharmaceuticals Recent Development

11.6 Novartis

11.6.1 Novartis Company Details

11.6.2 Novartis Business Overview

11.6.3 Novartis Gout Medications Introduction

11.6.4 Novartis Revenue in Gout Medications Business (2021–2026)

11.6.5 Novartis Recent Development

11.7 Wanbang Biopharmaceuticals

11.7.1 Wanbang Biopharmaceuticals Company Details

11.7.2 Wanbang Biopharmaceuticals Business Overview

11.7.3 Wanbang Biopharmaceuticals Gout Medications Introduction

11.7.4 Wanbang Biopharmaceuticals Revenue in Gout Medications Business (2021–2026)

11.7.5 Wanbang Biopharmaceuticals Recent Development

11.8 Hengrui Medicine

11.8.1 Hengrui Medicine Company Details

11.8.2 Hengrui Medicine Business Overview

11.8.3 Hengrui Medicine Gout Medications Introduction

11.8.4 Hengrui Medicine Revenue in Gout Medications Business (2021–2026)

11.8.5 Hengrui Medicine Recent Development

11.9 London Reddy

11.9.1 London Reddy Company Details

11.9.2 London Reddy Business Overview

11.9.3 London Reddy Gout Medications Introduction

11.9.4 London Reddy Revenue in Gout Medications Business (2021–2026)

11.9.5 London Reddy Recent Development

11.10 East Sunshine Pharmaceuticals

11.10.1 East Sunshine Pharmaceuticals Company Details

11.10.2 East Sunshine Pharmaceuticals Business Overview

11.10.3 East Sunshine Pharmaceuticals Gout Medications Introduction

11.10.4 East Sunshine Pharmaceuticals Revenue in Gout Medications Business (2021–2026)

11.10.5 East Sunshine Pharmaceuticals Recent Development

11.11 Kunming Pharmaceuticals

11.11.1 Kunming Pharmaceuticals Company Details

11.11.2 Kunming Pharmaceuticals Business Overview

11.11.3 Kunming Pharmaceuticals Gout Medications Introduction

11.11.4 Kunming Pharmaceuticals Revenue in Gout Medications Business (2021–2026)

11.11.5 Kunming Pharmaceuticals Recent Development

11.12 Heilongjiang Auridanide

11.12.1 Heilongjiang Auridanide Company Details

11.12.2 Heilongjiang Auridanide Business Overview

11.12.3 Heilongjiang Auridanide Gout Medications Introduction

11.12.4 Heilongjiang Auridanide Revenue in Gout Medications Business (2021–2026)

11.12.5 Heilongjiang Auridanide Recent Development

11.13 Jingde Pharmaceutical Factory

11.13.1 Jingde Pharmaceutical Factory Company Details

11.13.2 Jingde Pharmaceutical Factory Business Overview

11.13.3 Jingde Pharmaceutical Factory Gout Medications Introduction

11.13.4 Jingde Pharmaceutical Factory Revenue in Gout Medications Business (2021–2026)

11.13.5 Jingde Pharmaceutical Factory Recent Development

11.14 Tianjie Biopharmaceuticals

11.14.1 Tianjie Biopharmaceuticals Company Details

11.14.2 Tianjie Biopharmaceuticals Business Overview

11.14.3 Tianjie Biopharmaceuticals Gout Medications Introduction

11.14.4 Tianjie Biopharmaceuticals Revenue in Gout Medications Business (2021–2026)

11.14.5 Tianjie Biopharmaceuticals Recent Development

11.15 Shanghai Pharmaceuticals

11.15.1 Shanghai Pharmaceuticals Company Details

11.15.2 Shanghai Pharmaceuticals Business Overview

11.15.3 Shanghai Pharmaceuticals Gout Medications Introduction

11.15.4 Shanghai Pharmaceuticals Revenue in Gout Medications Business (2021–2026)

11.15.5 Shanghai Pharmaceuticals Recent Development

11.16 Chengdu Taihe Health

11.16.1 Chengdu Taihe Health Company Details

11.16.2 Chengdu Taihe Health Business Overview

11.16.3 Chengdu Taihe Health Gout Medications Introduction

11.16.4 Chengdu Taihe Health Revenue in Gout Medications Business (2021–2026)

11.16.5 Chengdu Taihe Health Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Teijin Pharma

Novartis

Hengrui Medicine

Takeda Pharmaceuticals

Aspen

Horizon Pharmaceuticals

Wanbang Biopharmaceuticals

Shanghai Pharmaceuticals

Hermann Germany

London Reddy

East Sunshine Pharmaceuticals

Kunming Pharmaceuticals

Heilongjiang Auridanide

Jingde Pharmaceutical Factory

Tianjie Biopharmaceuticals

Chengdu Taihe Health

List of Tables

Table 1. Global Gout Medications Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Febuxostat

Table 3. Key Players of Benzbromarone

Table 4. Key Players of NSAIDs

Table 5. Key Players of Colchicine

Table 6. Key Players of Glucocorticoids

Table 7. Key Players of Allopurinol

Table 8. Key Players of Other

Table 9. Global Gout Medications Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 10. Global Gout Medications Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 11. Global Gout Medications Market Size by Region (US$ Million), 2021–2026

Table 12. Global Gout Medications Market Share by Region (2021–2026)

Table 13. Global Gout Medications Forecasted Market Size by Region (US$ Million), 2027–2032

Table 14. Global Gout Medications Market Share by Region (2027–2032)

Table 15. Gout Medications Market Trends

Table 16. Gout Medications Market Drivers

Table 17. Gout Medications Market Challenges

Table 18. Gout Medications Market Restraints

Table 19. Global Gout Medications Revenue by Players (US$ Million), 2021–2026

Table 20. Global Gout Medications Market Share by Players (2021–2026)

Table 21. Global Top Gout Medications Players by Tier (Tier 1, Tier 2, and Tier 3), based on Gout Medications Revenue, 2025

Table 22. Ranking of Global Top Gout Medications Companies by Revenue (US$ Million) in 2025

Table 23. Global 5 Largest Players Market Share by Gout Medications Revenue (CR5 and HHI), 2021–2026

Table 24. Global Key Players of Gout Medications, Headquarters and Area Served

Table 25. Global Key Players of Gout Medications, Products and Applications

Table 26. Global Key Players of Gout Medications, Date of General Availability (GA)

Table 27. Mergers and Acquisitions, Expansion Plans

Table 28. Global Gout Medications Market Size by Type (US$ Million), 2021–2026

Table 29. Global Gout Medications Revenue Market Share by Type (2021–2026)

Table 30. Global Gout Medications Forecasted Market Size by Type (US$ Million), 2027–2032

Table 31. Global Gout Medications Revenue Market Share by Type (2027–2032)

Table 32. Global Gout Medications Market Size by Application (US$ Million), 2021–2026

Table 33. Global Gout Medications Revenue Market Share by Application (2021–2026)

Table 34. Global Gout Medications Forecasted Market Size by Application (US$ Million), 2027–2032

Table 35. Global Gout Medications Revenue Market Share by Application (2027–2032)

Table 36. North America Gout Medications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. North America Gout Medications Market Size by Country (US$ Million), 2021–2026

Table 38. North America Gout Medications Market Size by Country (US$ Million), 2027–2032

Table 39. Europe Gout Medications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 40. Europe Gout Medications Market Size by Country (US$ Million), 2021–2026

Table 41. Europe Gout Medications Market Size by Country (US$ Million), 2027–2032

Table 42. Asia-Pacific Gout Medications Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 43. Asia-Pacific Gout Medications Market Size by Region (US$ Million), 2021–2026

Table 44. Asia-Pacific Gout Medications Market Size by Region (US$ Million), 2027–2032

Table 45. Latin America Gout Medications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Latin America Gout Medications Market Size by Country (US$ Million), 2021–2026

Table 47. Latin America Gout Medications Market Size by Country (US$ Million), 2027–2032

Table 48. Middle East & Africa Gout Medications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 49. Middle East & Africa Gout Medications Market Size by Country (US$ Million), 2021–2026

Table 50. Middle East & Africa Gout Medications Market Size by Country (US$ Million), 2027–2032

Table 51. Takeda Pharmaceuticals Company Details

Table 52. Takeda Pharmaceuticals Business Overview

Table 53. Takeda Pharmaceuticals Gout Medications Product

Table 54. Takeda Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 55. Takeda Pharmaceuticals Recent Development

Table 56. Hermann Germany Company Details

Table 57. Hermann Germany Business Overview

Table 58. Hermann Germany Gout Medications Product

Table 59. Hermann Germany Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 60. Hermann Germany Recent Development

Table 61. Aspen Company Details

Table 62. Aspen Business Overview

Table 63. Aspen Gout Medications Product

Table 64. Aspen Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 65. Aspen Recent Development

Table 66. Teijin Pharma Company Details

Table 67. Teijin Pharma Business Overview

Table 68. Teijin Pharma Gout Medications Product

Table 69. Teijin Pharma Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 70. Teijin Pharma Recent Development

Table 71. Horizon Pharmaceuticals Company Details

Table 72. Horizon Pharmaceuticals Business Overview

Table 73. Horizon Pharmaceuticals Gout Medications Product

Table 74. Horizon Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 75. Horizon Pharmaceuticals Recent Development

Table 76. Novartis Company Details

Table 77. Novartis Business Overview

Table 78. Novartis Gout Medications Product

Table 79. Novartis Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 80. Novartis Recent Development

Table 81. Wanbang Biopharmaceuticals Company Details

Table 82. Wanbang Biopharmaceuticals Business Overview

Table 83. Wanbang Biopharmaceuticals Gout Medications Product

Table 84. Wanbang Biopharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 85. Wanbang Biopharmaceuticals Recent Development

Table 86. Hengrui Medicine Company Details

Table 87. Hengrui Medicine Business Overview

Table 88. Hengrui Medicine Gout Medications Product

Table 89. Hengrui Medicine Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 90. Hengrui Medicine Recent Development

Table 91. London Reddy Company Details

Table 92. London Reddy Business Overview

Table 93. London Reddy Gout Medications Product

Table 94. London Reddy Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 95. London Reddy Recent Development

Table 96. East Sunshine Pharmaceuticals Company Details

Table 97. East Sunshine Pharmaceuticals Business Overview

Table 98. East Sunshine Pharmaceuticals Gout Medications Product

Table 99. East Sunshine Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 100. East Sunshine Pharmaceuticals Recent Development

Table 101. Kunming Pharmaceuticals Company Details

Table 102. Kunming Pharmaceuticals Business Overview

Table 103. Kunming Pharmaceuticals Gout Medications Product

Table 104. Kunming Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 105. Kunming Pharmaceuticals Recent Development

Table 106. Heilongjiang Auridanide Company Details

Table 107. Heilongjiang Auridanide Business Overview

Table 108. Heilongjiang Auridanide Gout Medications Product

Table 109. Heilongjiang Auridanide Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 110. Heilongjiang Auridanide Recent Development

Table 111. Jingde Pharmaceutical Factory Company Details

Table 112. Jingde Pharmaceutical Factory Business Overview

Table 113. Jingde Pharmaceutical Factory Gout Medications Product

Table 114. Jingde Pharmaceutical Factory Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 115. Jingde Pharmaceutical Factory Recent Development

Table 116. Tianjie Biopharmaceuticals Company Details

Table 117. Tianjie Biopharmaceuticals Business Overview

Table 118. Tianjie Biopharmaceuticals Gout Medications Product

Table 119. Tianjie Biopharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 120. Tianjie Biopharmaceuticals Recent Development

Table 121. Shanghai Pharmaceuticals Company Details

Table 122. Shanghai Pharmaceuticals Business Overview

Table 123. Shanghai Pharmaceuticals Gout Medications Product

Table 124. Shanghai Pharmaceuticals Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 125. Shanghai Pharmaceuticals Recent Development

Table 126. Chengdu Taihe Health Company Details

Table 127. Chengdu Taihe Health Business Overview

Table 128. Chengdu Taihe Health Gout Medications Product

Table 129. Chengdu Taihe Health Revenue in Gout Medications Business (US$ Million), 2021–2026

Table 130. Chengdu Taihe Health Recent Development

Table 131. Research Programs/Design for This Report

Table 132. Key Data Information from Secondary Sources

Table 133. Key Data Information from Primary Sources

Table 134. Authors List of This Report

List of Figures

Figure 1. Gout Medications Picture

Figure 2. Global Gout Medications Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Gout Medications Market Share by Type: 2025 vs 2032

Figure 4. Febuxostat Features

Figure 5. Benzbromarone Features

Figure 6. NSAIDs Features

Figure 7. Colchicine Features

Figure 8. Glucocorticoids Features

Figure 9. Allopurinol Features

Figure 10. Other Features

Figure 11. Global Gout Medications Market Size by Application (US$ Million), 2021–2032

Figure 12. Global Gout Medications Market Share by Application: 2025 vs 2032

Figure 13. Primary Gout Case Studies

Figure 14. Secondary Gout Case Studies

Figure 15. Gout Medications Report Years Considered

Figure 16. Global Gout Medications Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 17. Global Gout Medications Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 18. Global Gout Medications Market Share by Region: 2025 vs 2032

Figure 19. Global Gout Medications Market Share by Players in 2025

Figure 20. Global Gout Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 21. The Top 10 and 5 Players Market Share by Gout Medications Revenue in 2025

Figure 22. North America Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. North America Gout Medications Market Share by Country (2021–2032)

Figure 24. United States Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Canada Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. Europe Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Europe Gout Medications Market Share by Country (2021–2032)

Figure 28. Germany Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. France Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. U.K. Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Italy Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Russia Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Ireland Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Asia-Pacific Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Asia-Pacific Gout Medications Market Share by Region (2021–2032)

Figure 36. China Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Japan Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. South Korea Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Southeast Asia Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. India Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Australia & New Zealand Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Latin America Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Latin America Gout Medications Market Share by Country (2021–2032)

Figure 44. Mexico Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Brazil Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Middle East & Africa Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Middle East & Africa Gout Medications Market Share by Country (2021–2032)

Figure 48. Israel Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Saudi Arabia Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. UAE Gout Medications Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Takeda Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 52. Hermann Germany Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 53. Aspen Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 54. Teijin Pharma Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 55. Horizon Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 56. Novartis Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 57. Wanbang Biopharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 58. Hengrui Medicine Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 59. London Reddy Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 60. East Sunshine Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 61. Kunming Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 62. Heilongjiang Auridanide Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 63. Jingde Pharmaceutical Factory Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 64. Tianjie Biopharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 65. Shanghai Pharmaceuticals Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 66. Chengdu Taihe Health Revenue Growth Rate in Gout Medications Business (2021–2026)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions